DaVita board authorizes additional $2 billion share repurchase program

DaVita Inc. (NYSE: DVA) announced that its board of directors increased authorization under the company's existing share repurchase program by $2 billion on August 20, 2025.

The new authorization is separate from the company's existing share repurchase program that was authorized on September 5, 2024. Both authorizations do not have expiration dates and do not require the company to purchase any shares.

Share repurchases may occur through open market transactions or privately negotiated deals, including through DaVita's share repurchase agreement with Berkshire Hathaway Inc. dated April 30, 2024. The company may also use accelerated share repurchase transactions, derivative transactions, tender offers, or Rule 10b5-1 plans.

The dialysis provider stated that the number of shares to be repurchased, the total dollar amount of purchases, and the disposition of purchased shares remains uncertain. Repurchases depend on market conditions, regulatory requirements, legal constraints, and other factors.

DaVita retains the ability to suspend, discontinue, or modify the authorization amounts at any time. The company remains subject to share repurchase limitations under its current senior secured credit facilities.

The information was disclosed in a company statement.

You May Also Be Interested In